BioAge Labs, Inc. (BIOA) Wednesday announced a multi-year collaboration with Novartis to discover and validate multiple therapeutic drug therapies for age-related diseases and conditions.
Currently, BIOA is trading at $4.22, up 3.11 percent on a volume of 2,560,920.
As per the agreement, BioAge will receive upfront payments and research funding of up to $20 million, plus up to $530 million in future long-term milestones. The collaboration will be eligible for reciprocal success milestones and tiered royalties.
Collaboration is expected to leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets.
The collaboration will leverage BioAge's extensive proprietary human longevity datasets and Novartis expertise in exercise biology.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.